24 research outputs found

    Regional Differences in Life Expectancy in Russia Through the Lens of Epidemiological Transition

    Full text link
    Received 16 February 2024. Accepted 13 May 2024. Published online 21 July 2024.An immense territory of Russia with several climatic zones and, accordingly, a fundamentally different styles of life, inevitably results in pronounced varieties in the levels and structure of mortality across the regions of the country. Since the scale and sustainability of differences in mortality in Russia can be considered an entire epidemiological epoch, the evaluation of them through the lens of epidemiological transition seems methodologically appropriate. Regional differences are regarded as a kind of projection of evolution in time, though taking into account modern realities. The analysis of regional differences in mortality is based on such indicators as life expectancy, structure of mortality, i.e., predominantly endogenous to exogenous causes of death ratio, as well as the average age of death from predominantly endogenous causes calculated on the basis of life tables by cause of death. The study showed that according to the periodization of epidemiological transition only Moscow and St. Petersburg are at the final phase of the 3rd stage and are moving to the 4th stage of epidemiological development. Meanwhile, the burden of exogenous and preventable pathologies precludes the completion of the 3rd stage in the regions with high life expectancy according to Russian criteria. The stadial nature of epidemiologic development of Russian regions is currently conditioned by socio-economic and medical determinants, with more pressing medical determinants in regions with high and medium levels of life expectancy and socio-economic factors prevailing in regions with low life expectancy

    ΠœΠ°Ρ€ΠΊΠ΅Ρ€Ρ‹ ΠΏΠΎΡ‡Π΅Ρ‡Π½ΠΎΠ³ΠΎ поврСТдСния, Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΊΠ°Ρ€Π±ΠΎΠ½ΠΈΠ»ΡŒΠ½ΠΎΠ³ΠΎ стрСсса Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с сахарным Π΄ΠΈΠ°Π±Π΅Ρ‚ΠΎΠΌ I Ρ‚ΠΈΠΏΠ° ΠΈ Ρ€Π°Π·Π½Ρ‹ΠΌ ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ Π°Π»ΡŒΠ±ΡƒΠΌΠΈΠ½ΡƒΡ€ΠΈΠΈ

    Get PDF
    The aim of this work was to study the levels of podocalyxin and Ξ²-2-microglobulin and parameters of lipid metabolism and carbonyl stress in type 1 diabetes mellitus (T1DM) patients with different levels of albuminuria.Materials and methods. 56 men of reproductive age with T1DM were divided into two groups: 24 patients with stage A1 albuminuria (group A1) and 32 patients with stage A2 albuminuria (group A2). The control group consisted of 28 healthy men. The levels of renal function markers, lipid metabolism parameters, and methylglyoxal were assessed using enzyme immunoassay and spectrophotometric and fluorometric methods.Results. Higher values for total cholesterol, triacylglycerol, and very-low-density lipoprotein medians in both groups A1 and A2 were found. In these groups, increased podocalyxin and methylglyoxal medians were revealed. Correlation analysis in the group A1 showed the presence of a relationship between the glomerular filtration rate (GFR) and creatinine. In the group A2, correlations between the generally accepted parameters of kidney injury (the albumin / creatinine ratio and GFR) and the duration of the disease and between GFR and the creatinine and methylglyoxal levels in the blood were identified. The podocalyxin level in this group correlated with the Ξ²2- microglobulin and methylglyoxal levels and lipid metabolism parameters. The level of Ξ²2-microglobulin correlated with the lipid metabolism parameters.Conclusion. Regardless of the level of albuminuria, men with T1DM had significantly increased levels of podocalyxin, lipid metabolism parameters, and methylglyoxal, as well as strong relationships between these parameters. The data of this study can be used for development of potential strategies for prevention and early treatment of diabetic nephropathy.ЦСль – ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ уровня подокаликсина, Ξ²-2-ΠΌΠΈΠΊΡ€ΠΎΠ³Π»ΠΎΠ±ΡƒΠ»ΠΈΠ½Π°, ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΊΠ°Ρ€Π±ΠΎΠ½ΠΈΠ»ΡŒΠ½ΠΎΠ³ΠΎ стрСсса Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с сахарным Π΄ΠΈΠ°Π±Π΅Ρ‚ΠΎΠΌ (Π‘Π”) I Ρ‚ΠΈΠΏΠ° ΠΈ Ρ€Π°Π·Π½Ρ‹ΠΌ ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ Π°Π»ΡŒΠ±ΡƒΠΌΠΈΠ½ΡƒΡ€ΠΈΠΈ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ обслСдованиС 56 ΠΌΡƒΠΆΡ‡ΠΈΠ½ Ρ€Π΅ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ возраста с Π‘Π” I Ρ‚ΠΈΠΏΠ°, Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Π½Ρ‹Ρ… Π½Π° Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹: 24 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° с Π°Π»ΡŒΠ±ΡƒΠΌΠΈΠ½ΡƒΡ€ΠΈΠ΅ΠΉ стадии А1 (Π³Ρ€ΡƒΠΏΠΏΠ° А1) ΠΈ 32 – с Π°Π»ΡŒΠ±ΡƒΠΌΠΈΠ½ΡƒΡ€ΠΈΠ΅ΠΉ стадии А2 (Π³Ρ€ΡƒΠΏΠΏΠ° А2). ΠšΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒΠ½ΡƒΡŽ Π³Ρ€ΡƒΠΏΠΏΡƒ составили 28 Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… ΠΌΡƒΠΆΡ‡ΠΈΠ½. ΠžΡ†Π΅Π½ΠΈΠ²Π°Π»ΡΡ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΏΠΎΡ‡Π΅Ρ‡Π½Ρ‹Ρ… ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ², ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ мСтилглиоксаля (ΠœΠ“) с использованиСм ΠΈΠΌΠΌΡƒΠ½ΠΎΡ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚Π½Ρ‹Ρ…, спСктрофотомСтричСских ΠΈ Ρ„Π»ΡŽΠΎΡ€ΠΎΠΌΠ΅Ρ‚Ρ€ΠΈΡ‡Π΅ΡΠΊΠΈΡ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ².Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. УстановлСны Π±ΠΎΠ»Π΅Π΅ высокиС значСния ΠΌΠ΅Π΄ΠΈΠ°Π½ ΠΎΠ±Ρ‰Π΅Π³ΠΎ холСстСрина, Ρ‚Ρ€ΠΈΠ°Ρ†ΠΈΠ»Π³Π»ΠΈΡ†Π΅Ρ€ΠΈΠ΄ΠΎΠ² ΠΈ Π»ΠΈΠΏΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΈΠ΄ΠΎΠ² ΠΎΡ‡Π΅Π½ΡŒ Π½ΠΈΠ·ΠΊΠΎΠΉ плотности Π² ΠΎΠ±Π΅ΠΈΡ… Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… с Π‘Π” I Ρ‚ΠΈΠΏΠ°. Π’ Π΄Π°Π½Π½Ρ‹Ρ… Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… ΠΎΡ‚ΠΌΠ΅Ρ‡Π°Π»ΠΈΡΡŒ Ρ‚Π°ΠΊΠΆΠ΅ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½Ρ‹Π΅ значСния ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ‹ подокаликсина ΠΈ основного показатСля ΠΊΠ°Ρ€Π±ΠΎΠ½ΠΈΠ»ΡŒΠ½ΠΎΠ³ΠΎ стрСсса – ΠœΠ“. ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π½Ρ‹ΠΉ коррСляционный Π°Π½Π°Π»ΠΈΠ· Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ А1 ΠΏΠΎΠΊΠ°Π·Π°Π» Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ зависимости уровня скорости ΠΊΠ»ΡƒΠ±ΠΎΡ‡ΠΊΠΎΠ²ΠΎΠΉ Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ†ΠΈΠΈ (БКЀ) ΠΈ ΠΊΡ€Π΅Π°Ρ‚ΠΈΠ½ΠΈΠ½Π°. Π’ Π³Ρ€ΡƒΠΏΠΏΠ΅ А2 ΠΎΡ‚ΠΌΠ΅Ρ‡Π°Π»ΠΈΡΡŒ связи общСпринятых ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ ΠΏΠΎΡ‡Π΅Ρ‡Π½ΠΎΠ³ΠΎ поврСТдСния (ΡΠΎΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΡ Π°Π»ΡŒΠ±ΡƒΠΌΠΈΠ½/ΠΊΡ€Π΅Π°Ρ‚ΠΈΠ½ΠΈΠ½ ΠΈ БКЀ) с Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒΡŽ заболСвания, показатСля БКЀ с ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ ΠΊΡ€Π΅Π°Ρ‚ΠΈΠ½ΠΈΠ½Π° ΠΈ ΠœΠ“. Π£Ρ€ΠΎΠ²Π΅Π½ΡŒ подокаликсина Π² Π΄Π°Π½Π½ΠΎΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ ΠΊΠΎΡ€Ρ€Π΅Π»ΠΈΡ€ΠΎΠ²Π°Π» с ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ Ξ²2-ΠΌΠΈΠΊΡ€ΠΎΠ³Π»ΠΎΠ±ΡƒΠ»ΠΈΠ½Π°, ΠœΠ“, ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°; Ξ²2-ΠΌΠΈΠΊΡ€ΠΎΠ³Π»ΠΎΠ±ΡƒΠ»ΠΈΠ½ ΠΈΠΌΠ΅Π» взаимосвязи с ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π£ ΠΌΡƒΠΆΡ‡ΠΈΠ½ с Π‘Π” I Ρ‚ΠΈΠΏΠ° Π²Π½Π΅ зависимости ΠΎΡ‚ уровня Π°Π»ΡŒΠ±ΡƒΠΌΠΈΠ½ΡƒΡ€ΠΈΠΈ ΠΎΡ‚ΠΌΠ΅Ρ‡Π°ΡŽΡ‚ΡΡ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ высокий ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ подокаликсина, ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½Π½Ρ‹Π΅ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠœΠ“, Π° Ρ‚Π°ΠΊΠΆΠ΅ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ тСсных взаимосвязСй ΠΌΠ΅ΠΆΠ΄Ρƒ этими ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌΠΈ, Ρ‡Ρ‚ΠΎ ΠΌΠΎΠΆΠ΅Ρ‚ Π±Ρ‹Ρ‚ΡŒ использовано для Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… стратСгий ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ ΠΈ Ρ€Π°Π½Π½Π΅ΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ диабСтичСской Π½Π΅Ρ„Ρ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ

    ИспользованиС Π½ΠΈΠ·ΠΊΠΎΠ±Π΅Π»ΠΊΠΎΠ²Ρ‹Ρ… ΠΎΠ±ΠΎΠ³Π°Ρ‰Π΅Π½Π½Ρ‹Ρ… ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΠΌΡƒΡ‡Π½Ρ‹Ρ… ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² Π² Π΄ΠΈΠ΅Ρ‚ΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Ρ„Π΅Π½ΠΈΠ»ΠΊΠ΅Ρ‚ΠΎΠ½ΡƒΡ€ΠΈΠ΅ΠΉ Π΄Π΅Ρ‚Π΅ΠΉ Π² возрастС ΡΡ‚Π°Ρ€ΡˆΠ΅ 1 Π³ΠΎΠ΄Π°

    Get PDF
    Background. The nutrition of children with phenylketonuria includes specialized starch-based products, the range of which is constantly expanding. Our aim was to study the safety of the composition of starchy flakes enriched with a complex of fat-soluble vitamins, natural fruit and berry additives used in the food of children with phenylketonuria. Methods. The study included children under the age of 14 years who were compliant with the previously conducted hypophenylalanine diet, without acute infectious, severe somatic or neurological diseases. The investigated products (starch-rye, wheat, and wheat fruit flakes with a complex of provitamin A and vitamin E) were prescribed instead of previously used low-protein confectionery products in the amount of 20–25 g/day for children under 6 years, 30–40 g β€” for children aged 6 years and over. The products were given with the recommendation to use alternately, with a duration of at least 10 days, totally for 30 days of the study. The safety of the products was assessed by phenylalanine concentration in the blood (determined by the fluorimetric method). In addition, we assessed the organoleptic qualities of the products and the dynamics of physical development of children. Results. The study included 15 children, mean age 4.4 Β± 1.9 years. The initial concentration of phenylalanine in the blood varied from 1.6 to 3.9 mg%, the median β€” 2.2 mg% (2.0; 2.8). In 30 days after inclusion of starchy flakes in the diet, the content of phenylalanine in the blood did not change and was 2.5 mg% (2.2; 2.7); p = 0.859. The organoleptic properties of the products were rated Β«excellentΒ» by all patients and their parents (in children under 6 years, only according to the parents’ assessment). The indicators of physical development did not change. There was no adverse events (allergic reactions, dyspepsia, refusal to take food). Conclusion. Introduction of new functional products β€” low-protein starchy flakes enriched with a vitamin complex and natural fruit and berry additives β€” in the diet of children with phenylketonuria allows to maintain the level of phenylalanine in the blood at the level of reference values.ОбоснованиС. Π’ ΠΏΠΈΡ‚Π°Π½ΠΈΠΈ Π΄Π΅Ρ‚Π΅ΠΉ с Ρ„Π΅Π½ΠΈΠ»ΠΊΠ΅Ρ‚ΠΎΠ½ΡƒΡ€ΠΈΠ΅ΠΉ ΡˆΠΈΡ€ΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΡŽΡ‚ спСциализированныС ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ‹ Π½Π° основС ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΠ², ассортимСнт ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… постоянно Ρ€Π°ΡΡˆΠΈΡ€ΡΠ΅Ρ‚ΡΡ.ЦСль исслСдования β€” ΠΈΠ·ΡƒΡ‡ΠΈΡ‚ΡŒ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ‚ΡŒ состава Ρ…Π»ΠΎΠΏΡŒΠ΅Π² ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΠΌΡƒΡ‡Π½Ρ‹Ρ…, ΠΎΠ±ΠΎΠ³Π°Ρ‰Π΅Π½Π½Ρ‹Ρ… комплСксом Тирорастворимых Π²ΠΈΡ‚Π°ΠΌΠΈΠ½ΠΎΠ², Π½Π°Ρ‚ΡƒΡ€Π°Π»ΡŒΠ½Ρ‹ΠΌΠΈ ΠΏΠ»ΠΎΠ΄ΠΎΠ²Ρ‹ΠΌΠΈ ΠΈ ягодными Π΄ΠΎΠ±Π°Π²ΠΊΠ°ΠΌΠΈ, ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… Π² ΠΏΠΈΡ‰Π΅ Π΄Π΅Ρ‚Π΅ΠΉ с Ρ„Π΅Π½ΠΈΠ»ΠΊΠ΅Ρ‚ΠΎΠ½ΡƒΡ€ΠΈΠ΅ΠΉ.ΠœΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡Π°Π»ΠΈ Π΄Π΅Ρ‚Π΅ΠΉ Π² возрастС Π΄ΠΎ 14 Π»Π΅Ρ‚, ΠΊΠΎΠΌΠΏΠ»Π°Π΅Π½Ρ‚Π½Ρ‹Ρ… ΠΊ Ρ€Π°Π½Π΅Π΅ ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ Π³ΠΈΠΏΠΎΡ„Π΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½ΠΎΠ²ΠΎΠΉ Π΄ΠΈΠ΅Ρ‚Π΅, Π±Π΅Π· острых ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ…, тяТСлых соматичСских ΠΈΠ»ΠΈ нСврологичСских Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. Π˜ΡΡΠ»Π΅Π΄ΡƒΠ΅ΠΌΡ‹Π΅ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ‹ β€” ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΡ€ΠΆΠ°Π½Ρ‹Π΅, ΠΏΡˆΠ΅Π½ΠΈΡ‡Π½Ρ‹Π΅ ΠΈ ΠΏΡˆΠ΅Π½ΠΈΡ‡Π½Ρ‹Π΅ ΠΏΠ»ΠΎΠ΄ΠΎΠ²ΠΎ-ягодныС Ρ…Π»ΠΎΠΏΡŒΡ с комплСксом ΠΏΡ€ΠΎΠ²ΠΈΡ‚Π°ΠΌΠΈΠ½Π° А ΠΈ Π²ΠΈΡ‚Π°ΠΌΠΈΠ½Π° Π• β€” Π½Π°Π·Π½Π°Ρ‡Π°Π»ΠΈ Π²Π·Π°ΠΌΠ΅Π½ ΠΏΡ€ΠΈΠΌΠ΅Π½ΡΠ²ΡˆΠΈΡ…ΡΡ Ρ€Π°Π½Π΅Π΅ Π½ΠΈΠ·ΠΊΠΎΠ±Π΅Π»ΠΊΠΎΠ²Ρ‹Ρ… кондитСрских ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ Π² количСствС 20–25 Π³/сут дСтям младшС 6 Π»Π΅Ρ‚, ΠΏΠΎ 30–40 Π³ β€” дСтям, Π΄ΠΎΡΡ‚ΠΈΠ³ΡˆΠΈΡ… возраста ΠΈΠ»ΠΈ ΡΡ‚Π°Ρ€ΡˆΠ΅ 6 Π»Π΅Ρ‚. ΠŸΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ‹ Π²Ρ‹Π΄Π°Π²Π°Π»ΠΈ с Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠ΅ΠΉ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Ρ‚ΡŒ ΠΏΠΎΠΎΡ‡Π΅Ρ€Π΅Π΄Π½ΠΎ, ΠΏΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒΡŽ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 10 сут, всСго Π½Π° 30 сут исслСдования. Π‘Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ‚ΡŒ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ Ρ„Π΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡ€ΠΎΠ²ΠΈ (опрСдСляли Ρ„Π»ΡŽΠΎΡ€ΠΈΠΌΠ΅Ρ‚Ρ€ΠΈΡ‡Π΅ΡΠΊΠΈΠΌ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ). Π”ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ органолСптичСскиС качСства ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² ΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ физичСского развития Π΄Π΅Ρ‚Π΅ΠΉ.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π’ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡ΠΈΠ»ΠΈ 15 Π΄Π΅Ρ‚Π΅ΠΉ, срСдний возраст 4,4Β±1,9 Π³ΠΎΠ΄Π°. Π˜ΡΡ…ΠΎΠ΄Π½Π°Ρ концСнтрация Ρ„Π΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡ€ΠΎΠ²ΠΈ Π²Π°Ρ€ΡŒΠΈΡ€ΠΎΠ²Π°Π»Π° ΠΎΡ‚ 1,6 Π΄ΠΎ 3,9 ΠΌΠ³%, ΠΌΠ΅Π΄ΠΈΠ°Π½Π° β€” 2,2 ΠΌΠ³% (2,0; 2,8). Π§Π΅Ρ€Π΅Π· 30 сут послС Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ Π² Ρ€Π°Ρ†ΠΈΠΎΠ½ ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΠΌΡƒΡ‡Π½Ρ‹Ρ… Ρ…Π»ΠΎΠΏΡŒΠ΅Π² содСрТаниС Ρ„Π΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡ€ΠΎΠ²ΠΈ Π½Π΅ измСнилось ΠΈ составило 2,5 ΠΌΠ³% (2,2; 2,7); Ρ€=0,859. ΠžΡ€Π³Π°Π½ΠΎΠ»Π΅ΠΏΡ‚ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ свойства ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² Π±Ρ‹Π»ΠΈ ΠΎΡ†Π΅Π½Π΅Π½Ρ‹ Π½Π° Β«ΠΎΡ‚Π»ΠΈΡ‡Π½ΠΎΒ» всСми ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌΠΈ ΠΈ ΠΈΡ… родитСлями (Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ Π² возрастС Π΄ΠΎ 6 Π»Π΅Ρ‚ β€” Ρ‚ΠΎΠ»ΡŒΠΊΠΎ согласно ΠΎΡ†Π΅Π½ΠΊΠ΅ Ρ€ΠΎΠ΄ΠΈΡ‚Π΅Π»Π΅ΠΉ). ΠŸΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ физичСского развития Π½Π΅ измСнились. ΠΠ΅ΠΆΠ΅Π»Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ явлСния (аллСргичСскиС Ρ€Π΅Π°ΠΊΡ†ΠΈΠΈ, диспСпсии, ΠΎΡ‚ΠΊΠ°Π· ΠΎΡ‚ ΠΏΡ€ΠΈΠ΅ΠΌΠ° ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ²) Π½Π΅ зафиксированы.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅ Π² Ρ€Π°Ρ†ΠΈΠΎΠ½ Π΄Π΅Ρ‚Π΅ΠΉ с Ρ„Π΅Π½ΠΈΠ»ΠΊΠ΅Ρ‚ΠΎΠ½ΡƒΡ€ΠΈΠ΅ΠΉ Π½ΠΎΠ²Ρ‹Ρ… Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² β€” Ρ…Π»ΠΎΠΏΡŒΠ΅Π² ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΠΌΡƒΡ‡Π½Ρ‹Ρ… Π½ΠΈΠ·ΠΊΠΎΠ±Π΅Π»ΠΊΠΎΠ²Ρ‹Ρ…, ΠΎΠ±ΠΎΠ³Π°Ρ‰Π΅Π½Π½Ρ‹Ρ… Π²ΠΈΡ‚Π°ΠΌΠΈΠ½Π½Ρ‹ΠΌ комплСксом ΠΈ Π½Π°Ρ‚ΡƒΡ€Π°Π»ΡŒΠ½Ρ‹ΠΌΠΈ ΠΏΠ»ΠΎΠ΄ΠΎΠ²Ρ‹ΠΌΠΈ ΠΈ ягодными Π΄ΠΎΠ±Π°Π²ΠΊΠ°ΠΌΠΈ, позволяСт ΡΠΎΡ…Ρ€Π°Π½ΡΡ‚ΡŒ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ Ρ„Π΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡ€ΠΎΠ²ΠΈ Π½Π° ΡƒΡ€ΠΎΠ²Π½Π΅ рСфСрСнсных Π·Π½Π°Ρ‡Π΅Π½ΠΈΠΉ.ИБВОЧНИК Π€Π˜ΠΠΠΠ‘Π˜Π ΠžΠ’ΠΠΠ˜Π― Π Π°Π±ΠΎΡ‚Π° Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Π° ΠΏΡ€ΠΈ ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠ΅ Π³Ρ€Π°Π½Ρ‚Π° Π€Π΅Π΄Π΅Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ государствСнного Π½Π°ΡƒΡ‡Π½ΠΎΠ³ΠΎ учрСТдСния «ВсСроссийский Π½Π°ΡƒΡ‡Π½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Ρ‚Π΅Π»ΡŒΡΠΊΠΈΠΉ институт ΠΊΡ€Π°Ρ…ΠΌΠ°Π»ΠΎΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ²Β» Π€Π΅Π΄Π΅Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ агСнтства Π½Π°ΡƒΡ‡Π½Ρ‹Ρ… ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΉ (Московская ΠΎΠ±Π»Π°ΡΡ‚ΡŒ). Для Ρ†Π΅Π»Π΅ΠΉ исслСдования использовались ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ‹, Π±Π΅Π·Π²ΠΎΠ·ΠΌΠ΅Π·Π΄Π½ΠΎ прСдоставлСнныС ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»Π΅ΠΌ (ΠΎΠΏΡ‹Ρ‚Π½ΠΎΠ΅ производство ЀГНУ Β«Π’ΠΠ˜Π˜ΠšΒ» ЀАНО).ΠšΠžΠΠ€Π›Π˜ΠšΠ’ Π˜ΠΠ’Π•Π Π•Π‘ΠžΠ’ Π’.Π­. Π‘ΠΎΡ€ΠΎΠ²ΠΈΠΊ, Н.Н. Π‘Π΅ΠΌΡ‘Π½ΠΎΠ²Π°, О.Π›. Лукоянова, Н.Π“. Π—Π²ΠΎΠ½ΠΊΠΎΠ²Π°, Π’.Π’. Π‘ΡƒΡˆΡƒΠ΅Π²Π°, Π’.Н. Π‘Ρ‚Π΅ΠΏΠ°Π½ΠΎΠ²Π°, Π’.А. Π‘ΠΊΠ²ΠΎΡ€Ρ†ΠΎΠ²Π° β€” ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π½Π°ΡƒΡ‡Π½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Ρ‚Π΅Π»ΡŒΡΠΊΠΈΡ… Ρ€Π°Π±ΠΎΡ‚ ΠΏΡ€ΠΈ ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠ΅ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΉ Heinz, Semper, Π₯ΠΈΠΏΡ€ΠΎΠΊΠ° ΠΡƒΡ‚Ρ€ΠΈΡˆΠΈΠΎΠ½ Π˜ΡΡ‚ Π›ΠΈΠΌΠΈΡ‚Π΅Π΄. И.М. ГусСва, Π•.А. РославцСва, А.К. ГСворкян, Π‘.Π’. Π‘Ρ‹ΠΊΠΎΠ²Π°, Π’.Π“. Калинина, Π‘.Π“. КалинСнкова ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€Π΄ΠΈΠ»ΠΈ отсутствиС ΠΊΠΎΠ½Ρ„Π»ΠΈΠΊΡ‚Π° интСрСсов.Π’Π«Π ΠΠ–Π•ΠΠ˜Π• ΠŸΠ Π˜Π—ΠΠΠ’Π•Π›Π¬ΠΠžΠ‘Π’Π˜ Π’Ρ‹Ρ€Π°ΠΆΠ°Π΅ΠΌ Π±Π»Π°Π³ΠΎΠ΄Π°Ρ€Π½ΠΎΡΡ‚ΡŒ ΠΊ.ΠΌ.Π½. Π‘.Π“. КалинСнковой (Московский областной Π½Π°ΡƒΡ‡Π½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Ρ‚Π΅Π»ΡŒΡΠΊΠΈΠΉ клиничСский институт ΠΈΠΌ. М.Π€. Владимирского) Π·Π° участиС Π² Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½ΠΎΠΉ части Π΄Π°Π½Π½ΠΎΠ³ΠΎ исслСдования.Β 

    Ekaterinburg Atelier of Andrey Voronikhin

    Full text link
    Π Π°ΡΡΠΌΠ°Ρ‚Ρ€ΠΈΠ²Π°ΡŽΡ‚ΡΡ СкатСринбургскиС Ρ€Π°Π±ΠΎΡ‚Ρ‹, прямо ΠΈ косвСнно связанныС с ΠΈΠΌΠ΅Π½Π΅ΠΌ Π²Ρ‹Π΄Π°ΡŽΡ‰Π΅Π³ΠΎΡΡ русского Π·ΠΎΠ΄Ρ‡Π΅Π³ΠΎ, высказываСтся ΠΏΡ€Π΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΎ руководящСй Ρ€ΠΎΠ»ΠΈ самого Π°Ρ€Ρ…ΠΈΡ‚Π΅ΠΊΡ‚ΠΎΡ€Π°, ΠΊΡ€ΡƒΠ³Π° Π΅Π³ΠΎ Π΅Π΄ΠΈΠ½ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½ΠΈΠΊΠΎΠ² Π½Π° ΠΎΠ΄Π½ΠΎΠΌ ΠΈΠ· ΠΎΡ‚Ρ€Π΅Π·ΠΊΠΎΠ² Π΄Π΅ΡΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΡƒΡ€Π°Π»ΡŒΡΠΊΠΎΠΉ ΠΊΠ°Π·Π΅Π½Π½ΠΎΠΉ ΠΊΠ°ΠΌΠ½Π΅ΠΎΠ±Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ.The article describes some works made in Yekaterinburg and either directly or indirectly connected with the name of the outstanding Russian architect. The author considers the architect's leading role and his partners' role in the creation thereof during a historic period in the state stone working of the Urals

    PHARMACOLOGICAL CORRECTION OF CEREBRAL BLOOD FLOW DISTURBANCES IN WOMEN WITH ARTERIAL HYPERTENSION IN POSTMENOPAUSE

    No full text
    Aim: to study cerebral blood flow and cholesterol metabolism in menopausal women with arterial hypertension (AH); to evaluate dynamics of cerebral blood flow parameters and plasma lipid concentrations in these patients during 6-month antihypertensive and hypolipidemic therapy.Material and methods: 24 women with AH of I and II grade were examined. They were in postmenopausal period of life during 7,1Β±0,5 years. At the beginning of the study all women were prescribed moexipril as monotherapy, daily dose 7,5 – 15 mg. Patients with initial dislipidemia were prescribed lipid reducing drug atorvastatin in 10mg daily dose additionally to the antihypertensive therapy. Therefore all the patients were divided into two groups: I – monoteraphy with moexipril (13 people), II – combined therapy with moexipril and atorvastatin (11 people). At the beginning of the study and after 6 months all the patients passed through ultrasonic Dopplerography of vessels of head and neck, rheoencephalography, their lipoproteidogrammes were studied.Results: During 6-month therapy all the patients showed proved decrease in systolic and diastolic blood pressure, also positive dynamics of neuropsychological status, improvement in cerebral blood flow according to the results of Dopplerography of vessels and rheoencephalography. Normalization of plasma lipid spectrum was noted. More significant positive changes in cerebral hemodynamic parameters and plasma lipid spectrum were observed in patients, who received combined therapy with antihypertensive and lipid reducing drugs.Conclusion: Deterioration of cerebral hemodynamics is typical for women with long-lasting AH. The most positive influence on cerebral perfusion was received due to combined therapy with moexipril and atorvastatin

    Leprosy in the Guise of Skin Tuberculosis β€” Complexities of Diagnostics

    No full text
    Objective: demonstration of the case of the leprosy late diagnosis at the female patient previously watched with the diagnosis Β«skin tuberculosisΒ». Materials and Methods. A 69 years old female patient watched from 2011 to 2016 with the diagnosis Β«skin tuberculosisΒ» and was cured with weak effect; in 2016 the diagnosis Β«skin tuberculosisΒ» was not confirmed. She undergone assessment at the State Research Centre for Dermatovenereology and Cosmetology of the Ministry of Health of the Russian Federation. The assessment included bacterioscopy of skin scrapings, pathomorphological studies of biopsy samples, molecular genetic testing. Results. On the grounds of complaints, medical history, data of surveying and physical examination, results of the clinical-laboratory studies the following diagnosis was stated: Β«dimorphous leprosy, leprosy BB (multibacillary leprosy, border line leprosy, active stage). Conclusion. The present observation indicates that the variety of leprosy clinical presentations and lack of suspicions on account of this ultra-rare disease lead to late diagnosis

    Bladder cancer: treatment after progression. Results of the second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia

    Get PDF
    Objective. There is the second generalized analysis of administration of vinflunine in real clinical practice in Russia.Materials and methods. This analysis gathered 15 patients with urothelial carcinoma treated using this medicine in 8 cancer centers in Russia. We assessed efficacy, safety profile of vinflunine in this subset of patients.Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 73.3 %, one patient demonstrated complete response. Median of response duration accounts for 3.8 months. Six-month and 1-year survival rate made up 93.3 %. Adverse events were observed in 53.5 %, with only one episode of neutropenia 4 grade.Conclusion. In our second analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, we confirm expediency to administer of vinflunine for metastatic urothelial carcinoma
    corecore